Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • The Evolution of Gene Editing

    From a single breakthrough to a platform of technologies, gene editing is evolving as clinical progress begins to take hold.

    Read more

  • 365 Retail Markets Has Acquired Cantaloupe

    William Blair acted as financial advisor to 365 Retail Markets, LLC, a portfolio company of Providence Equity Partners L.L.C., in connection with its acquisition of Cantaloupe, Inc. (NASDAQ: CTLP).

    Read more

  • Women’s Philanthropy in Action

    Laura Coy, partner, head of philanthropy and sustainability, shares how women, poised to hold a greater share of wealth in the years ahead, are driving trends in philanthropy.

    Watch the video
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures